The French Compassionate Program "Temporary Authorization For Use" And Thereafter... How Can It Affect Drug Market Access?
OBJECTIVES: "Temporary Authorization for Use" (ATU) is a French compassionate program allowing the use of drugs before their marketing authorization (MA). Only hospital pharmacies are allowed to deliver these drugs, even for outpatients. After the MA, the reimbursement is maintained during...
Gespeichert in:
Veröffentlicht in: | Value in health 2017-10, Vol.20 (9), p.A685 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | OBJECTIVES: "Temporary Authorization for Use" (ATU) is a French compassionate program allowing the use of drugs before their marketing authorization (MA). Only hospital pharmacies are allowed to deliver these drugs, even for outpatients. After the MA, the reimbursement is maintained during the HTA assessment and national agreements on reimbursement and price. This period, so-called "post-ATU" and that has been reframed in 2014, should not excess 180 days as it sustains a "free pricing window" for pharmaceutical companies. The aim of this study is to assess the economic impact of the post-ATU period from the hospital perspective and to identify the determinants of its duration. METHODS: We included all drugs that have been through the post-ATU process since 2014. We censured data in May 2017. The financial impact was calculated for the 37 public hospitals of Paris (AP-HP), the largest university hospital in France. We conducted univariate analyses between potential explicative variables and wait time to obtain price and reimbursement. Drugs prices were based on APHP's acquisition prices. RESULTS: 62 International Nonproprietary Name (INN) have been through the post-ATU period, among which 26 are still on the post-ATU list. In 2016, post-ATU expenditures have totalized f 85.2 million for AP-HP (8,4% of APHP's drug global budget). The post-ATU period has lasted 469 days in average (median: 446; min: 92; max: 1064). Only 1 INN has respected the regulatory deadlines. There is a significant correlation between increasing of post-ATU duration and orphan drugs status (p value = 0.01). There is no correlation with therapeutic areas, and surprisingly, no correlation with drug prices. CONCLUSIONS: Post-ATU drugs represent an important financial burden for hospitals whereas these drugs are still under a derogation procedure. Results showed the difficulty to sustain innovation without create perverse effects as the duration found here is largely higher than usual delays of negotiation. |
---|---|
ISSN: | 1098-3015 1524-4733 |
DOI: | 10.1016/j.jval.2017.08.1727 |